Journal Information
Vol. 43. Issue 6.
Pages 297-299 (January 2007)
Vol. 43. Issue 6.
Pages 297-299 (January 2007)
Editorial
Full text access
Anticholinergics in the Management of COPD
Visits
4456
Inmaculada Alfageme Michavila
Sección de Neumología, Hospital Universitario de Valme, Sevilla, Spain
This item has received
Article information
Full text is only available in PDF
REFERENCES
[1]
Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
[2]
PM Calverley, PS Burge, S Spencer, JA Anderson, PW Jones.
Bronchodilator reversibility testing in chronic obstructive pulmonary disease.
Thorax, 58 (2003), pp. 659-664
[3]
A Corsico, M Milanese, S Baraldo, et al.
Small airway morphology and lung function in the transition from normality to chronic airway obstruction.
J Appl Physiol, 95 (2003), pp. 441-447
[4]
RH Moreno, JC Hogg, PD Pare.
Mechanics of airway narrowing.
Am Rev Respir Dis, 133 (1986), pp. 1171-1180
[5]
NJ Gross.
Tiotropium bromide.
Chest, 126 (2004), pp. 1946-1953
[6]
JL Izquierdo Alonso, R Malo de Molina.
Otras formas de broncodilatación.
Arch Bronconeumol, 40 (2004), pp. 23-29
[7]
ER Sutherland, RM Cherniack.
Management of chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 2689-2697
[8]
R Casaburi, DA Mahler, PW Jones, et al.
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Eur Respir J, 19 (2002), pp. 217-224
[9]
DE O'Donnell, T Fluge, F Gerken, et al.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J, 23 (2004), pp. 832-848
[10]
B Celli, R ZuWallack, S Wang, S Kesten.
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
Chest, 124 (2003), pp. 1743-1748
[11]
V Brusasco, R Hodder, M Miravitlles, et al.
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Thorax, 58 (2003), pp. 399-404
[12]
W Vincken, JA van Noord, APM Greefhorst, et al.
Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium.
Eur Respir J, 19 (2002), pp. 209-216
[13]
D Dusser, ML Bravo, P Iacono, on behalf the MISTRAL study group.
The effect of tiotropium on exacerbations and airflow in patients with COPD.
Eur Respir J, 27 (2006), pp. 547-555
[14]
DE Niewoehner, K Rice, C Cote, D Paulson, JA Cooper Jr, L Korducki, et al.
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Ann Intern Med, 143 (2005), pp. 317-326
[15]
RG Barr, J Bourbeau, CA Camargo, FSF Ram.
Tiotropio inhalado para la enfermedad pulmonar obstructiva crónica estable (Translated Cochrane review).
La Biblioteca Cochrane Plus, Update Software Ltd., (2006),
[16]
RG Barr, J Bourbeau, CA Camargo, FSF Ram.
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis.
Thorax, 61 (2006), pp. 854-862
[17]
A Anzueto, D Tashkin, S Menjoge, S Kesten.
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.
Pulm Pharmacol Ther, 18 (2005), pp. 75-81
[18]
Chronic obstructive pulmonary disease.
National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Managing stable COPD.
Thorax, 59 (2004), pp. 39-130
[19]
JB Oostenbrink, MP Rutten-van Mölken, MJ Al, JA van Noord, W Vincken.
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Eur Respir J, 23 (2004), pp. 241-249
[20]
M Friedman, SS Menjoge, SF Anton, S Kesten.
Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Pharmacoeconomics, 22 (2004), pp. 741-749
[21]
P de Lucas Ramos, M Miravitlles, JM Rodríguez González-Moro, J de Miguel Díez, S López Martín, G Sánchez Muñoz.
Análisis de costeefectividad del empleo de tiotropio versus ipratropio en el tratamiento de los pacientes con enfermedad pulmonar obstructiva crónica.
Pharmacoeconomics Spanish Research Articles, 1 (2004), pp. 123-130
[22]
AJ García Ruiz, F Leiva Fernández, F Martos Crespo.
Análisis del coste-eficacia del tiotropio frente al ipratropio y salmeterol.
Arch Bronconeumol, 41 (2005), pp. 242-248
[23]
JA van Noord, JL Aumann, E Janssens, JJ Smeets, J Verhaert, B Disse, et al.
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
Eur Respir J, 26 (2005), pp. 214-222
[24]
M Cazzola, P Noschese, A Salzillo, et al.
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Respir Med, 99 (2005), pp. 524-528
[25]
A Baloira Villar, C Vilarino Pombo.
Eficacia broncodilatadora de la asociación de salmeterol y tiotropio en pacientes con EPOC.
Arch Bronconeumol, 41 (2005), pp. 130-134
[26]
DE O'Donnell.
Is sustained pharmacologic lung volume reduction now possible in COPD?.
Chest, 129 (2006), pp. 501-503
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?